Evidence map›Paper›PMID 38534930›Full record

ArticleCurrent oncology (Toronto, Ont.)2024

Timing of Surgery and Social Determinants of Health Related to Pathologic Complete Response after Total Neoadjuvant Therapy for Rectal Adenocarcinoma: Retrospective Study of National Cancer Database.

Megan Mai, Jodi Goldman, Duke Appiah, Ramzi Abdulrahman, John Kidwell, Zheng Shi

Open access · goldAbstract read
In one paragraph

Article in Current oncology (Toronto, Ont.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Megan MaiSchool of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.
Jodi GoldmanSchool of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.
Duke AppiahDepartment of Public Health, School of Population and Public Health, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.
Ramzi AbdulrahmanSchool of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.ORCID 0000-0002-1670-3857
John KidwellSchool of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.ORCID 0000-0001-9573-9665
Zheng ShiSchool of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.
Texas Tech University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Total neoadjuvant therapy (TNT) for rectal adenocarcinoma (RAC) involves multi-agent chemotherapy and radiation before definitive surgery. Previous studies of the rest period (time between radiation and surgery) and pathologic complete response (pCR) have produced mixed results. The objective of this study was to evaluate the relationship between the rest period and pCR. This study utilized the National Cancer Database (NCDB) to retrospectively analyze 5997 stage-appropriate RAC cases treated with TNT from 2016 to 2020. The overall pCR rate was 18.6%, with most patients undergoing induction chemotherapy followed by long-course chemoradiation (81.5%). Multivariable logistic regression models revealed a significant non-linear relationship between the rest period and pCR (

Indexed as

AdenocarcinomaRectal NeoplasmsHumansNeoadjuvant TherapyPathologic Complete ResponseRetrospective StudiesSocial Determinants of Healthpathologic complete responserectal cancertotal neoadjuvant therapy

Identifiers

PMID38534930
PMCPMC10969721
OpenAlexW4392297116

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.